The biotech mergers and acquisitions market currently faces significant headwinds. These challenges include frozen capital markets, regulatory uncertainty at the Food and Drug Administration (FDA) and Department of Health and Human Services (HHS), and tariffs. During this challenging time, there are several strategies that boards and management teams of biotech companies can consider to be well positioned to maximize value when opportunity arises — one of which is planning for creative deal structures. This article discusses spin-off transactions for biotechs.
Read the full article: Biotech Spin-Off Transactions //
Source: https://www.lexology.com/library/detail.aspx?g=e0ab0404-718a-431a-9c69-64d9e2289f90